• LAST PRICE
    17.5900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 17.5900
  • Day Range
    ---
  • 52 Week Range
    Low 9.9300
    High 32.9400
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesZEAL
Zealand Pharma A/S
786.8M
-5.4x
---
United StatesMNOV
MediciNova Inc
105.9M
-8.3x
---
United StatesVTVT
vTv Therapeutics Inc
94.1M
-3.6x
---
United StatesADVM
Adverum Biotechnologies Inc
90.9M
-0.6x
---
United StatesINFI
Infinity Pharmaceuticals Inc
103.6M
-2.3x
---
United StatesOCX
OncoCyte Corp
94.7M
-1.0x
---
As of 2022-10-04

Company Information

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Contact Information

Headquarters
Sydmarken 11SOEBORG, Denmark 2860
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Alf Nicklasson
President, Chief Executive Officer, Member of the Executive Management
Emmanuel Dulac
Independent Vice Chairman of the Board
Kirsten Drejer
Executive Vice President - Technical Development and Operations, Member of the Executive Management
Ivan Moeller
Executive Vice President - Research and Development, Chief Medical Officer, Member of the Executive Management
Adam Steensberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$786.8M
Revenue (TTM)
$26.3M
Shares Outstanding
46.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.45
EPS
$-3.24
Book Value
$2.77
P/E Ratio
-5.4x
Price/Sales (TTM)
29.9
Price/Cash Flow (TTM)
---
Operating Margin
-581.48%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.